Spinal Cord Stimulation in Chemotherapy Induced Neuropathy

Sponsor
Prisma Health-Upstate (Other)
Overall Status
Recruiting
CT.gov ID
NCT03764514
Collaborator
(none)
20
1
69.9
0.3

Study Details

Study Description

Brief Summary

This is an observational based pilot study evaluating the use of spinal cord stimulators for the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.

Condition or Disease Intervention/Treatment Phase
  • Device: Spinal Cord Stimulator

Detailed Description

Cancer treatment, for many patients, results in painful side effects. As evidence mounts demonstrating the risks associated with long term opioid therapy, non-opioid modalities need to be developed. Spinal cord stimulators are implanted devices that modulate the pain signaling system in the spinal cord. This research hopes to determine if the use of a spinal cord stimulator in patients with chemotherapy induced peripheral neuropathy will lead to an increase in quality of life and decrease in pain.The primary endpoints will be the number of patients who undergo permanent implantation. The endpoints will measure pain with the Brief Pain Inventory Short Form visual analog scale. The sleep quality will be measured using the Pittsburgh Sleep Quality Assessment.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effectiveness of Spinal Cord Stimulation as Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Pilot Trial
Actual Study Start Date :
Dec 3, 2018
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Spinal Cord Stimulator - Permanent Implantation

Device: Spinal Cord Stimulator
Permanent Implantation

Outcome Measures

Primary Outcome Measures

  1. Permanent Spinal Cord Stimulator Implantation [2 years]

    To determine the total number of patients who undergo permanent spinal cord stimulator implantation.

Secondary Outcome Measures

  1. Subjective Pain Assessment: Brief Pain Inventory-Short Form [2 years]

    Measure Pain with the Brief Pain Inventory-Short Form. The scale measures the severity of pain and the impact of pain on daily functions. The scale range includes 0-10 scales, with 0=no interference and 10=interferes completely. There is not a scoring algorithm, but "worst pain" or the average of the four severity items can be used as measures of pain severity; the average of the seven interference items can be used as a measure of pain interference.

  2. Subjective Quality of Life Assessment: Pittsburgh Sleep Quality Assessment [2 years]

    Measure quality of life through the use of the Pittsburgh Sleep Quality Assessment. The Pittsburgh Sleep Quality Index is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations.The 19 items are grouped into 7 components, including (1) sleep duration, (2) sleep disturbance, (3) sleep latency, (4) daytime dysfunction due to sleepiness, (5) sleep efficiency, (6) overall sleep quality, and (7) sleep medication use. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (global score) indicating worse sleep quality.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• The patient has persistent, severe peripheral neuropathy secondary to chemotherapy

Exclusion Criteria:

• Refusal to undergo a spinal cord stimulator procedure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Patewood Memorial Hospital Greenville South Carolina United States 29615

Sponsors and Collaborators

  • Prisma Health-Upstate

Investigators

  • Principal Investigator: Joshua Smith, MD, Prisma Health-Upstate

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prisma Health-Upstate
ClinicalTrials.gov Identifier:
NCT03764514
Other Study ID Numbers:
  • Pro00076097
First Posted:
Dec 5, 2018
Last Update Posted:
Jan 18, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2022